Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Ancient herb put to the test against hidden malaria

NCT ID NCT07819825

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time

Summary

Researchers in Gabon are testing whether a tea made from dried Artemisia annua leaves can clear malaria parasites in adults who carry the infection without feeling sick. The trial enrolls 20 semi-immune adults aged 18 to 45 who have low levels of Plasmodium falciparum in their blood. Participants drink the infusion daily for seven days, while a comparison group receives an herbal infusion with no known antimalarial effect. The team tracks whether parasites disappear and monitors for side effects over several weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Artemisia annua leaf infusion
What this could lead to
If the infusion clears parasites, it could offer a low-cost, plant-based treatment option for people who carry malaria without symptoms. That could help reduce the pool of infection in communities where the disease is common.
What could go wrong
This is a very small Phase 1 trial with only 20 participants, so results may not hold in larger groups. The infusion may not clear all parasites, and some people could experience side effects or see the infection return.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age: 18 to 45 years * Absence of fever (body temperature \<37.5ºC axillary or \<38.0°C oral, rectal or tympanic temperature) * Asymptomatic P. falciparum infection with parasitemia between 500 and 2,000 asexual P. falciparum parasites per μl of blood * Have been living in an endemic area for at least 5 years. * Written informed consent from the participant * Residence in the vicinity of the study centre * Willingness to comply with the follow-up schedule Exclusion Criteria: * History of fever over the last 72 hours * Non-Plasmodium falciparum infection * Intake of any antimalarial drug or antibiotic with antimalarial activity within the previous 28 days and/or after half-life time * Presence of signs and symptoms related by the medical doctor to malaria * Known history or evidence of clinically significant medical disorders * Severe malnutrition * Haemoglobin concentration \<7 g/dL * Known hypersensitivity and contraindications to any study medication * Pregnancy or lactation * Participation in other interventional studies

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asymptomatic P.falciparum malaria are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre de Recherches Médicales de Lambaréné

    Lambaréné, Gabon, BP: 242, Gabon